DK1786472T3 - Antisense-modulering af apolipoprotein B-ekspression - Google Patents
Antisense-modulering af apolipoprotein B-ekspressionInfo
- Publication number
- DK1786472T3 DK1786472T3 DK05784428.4T DK05784428T DK1786472T3 DK 1786472 T3 DK1786472 T3 DK 1786472T3 DK 05784428 T DK05784428 T DK 05784428T DK 1786472 T3 DK1786472 T3 DK 1786472T3
- Authority
- DK
- Denmark
- Prior art keywords
- apolipoprotein
- expression
- antisense modulation
- antisense
- modulation
- Prior art date
Links
- 101710095342 Apolipoprotein B Proteins 0.000 title 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 title 1
- 230000000692 anti-sense effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60078504P | 2004-08-10 | 2004-08-10 | |
US61283104P | 2004-09-23 | 2004-09-23 | |
PCT/US2005/028342 WO2006020676A2 (en) | 2004-08-10 | 2005-08-10 | Antisense modulation of apolipoprotein b expression |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1786472T3 true DK1786472T3 (da) | 2013-04-15 |
Family
ID=35908112
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15177512.9T DK2997980T3 (da) | 2004-08-10 | 2005-08-10 | Fremgangsmåder til modulation af liproprotein- og cholesterolniveauer hos mennesker |
DK05784428.4T DK1786472T3 (da) | 2004-08-10 | 2005-08-10 | Antisense-modulering af apolipoprotein B-ekspression |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15177512.9T DK2997980T3 (da) | 2004-08-10 | 2005-08-10 | Fremgangsmåder til modulation af liproprotein- og cholesterolniveauer hos mennesker |
Country Status (11)
Country | Link |
---|---|
US (3) | US20060035858A1 (da) |
EP (3) | EP1786472B1 (da) |
AU (1) | AU2005272912A1 (da) |
CA (1) | CA2576860A1 (da) |
DK (2) | DK2997980T3 (da) |
ES (3) | ES2401114T3 (da) |
HU (1) | HUE026284T2 (da) |
PL (2) | PL1786472T3 (da) |
PT (2) | PT1786472E (da) |
SI (1) | SI2409713T1 (da) |
WO (1) | WO2006020676A2 (da) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7888324B2 (en) * | 2001-08-01 | 2011-02-15 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
US7407943B2 (en) * | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
US20060009410A1 (en) * | 2002-11-13 | 2006-01-12 | Crooke Rosanne M | Effects of apolipoprotein B inhibition on gene expression profiles in animals |
US7511131B2 (en) | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
US20050287558A1 (en) | 2004-05-05 | 2005-12-29 | Crooke Rosanne M | SNPs of apolipoprotein B and modulation of their expression |
EP1786472B1 (en) * | 2004-08-10 | 2013-01-16 | Genzyme Corporation | Antisense modulation of apolipoprotein b expression |
EP2199298A1 (en) * | 2004-11-17 | 2010-06-23 | Protiva Biotherapeutics Inc. | Sirna silencing of Apolipoprotein B |
ATE494372T1 (de) * | 2005-08-29 | 2011-01-15 | Regulus Therapeutics Inc | Verfahren für mir-122a-modulation |
EP1931780B1 (en) * | 2005-08-29 | 2016-01-06 | Regulus Therapeutics Inc. | Antisense compounds having enhanced anti-microrna activity |
SG170773A1 (en) | 2006-04-03 | 2011-05-30 | Santaris Pharma As | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
EA015570B1 (ru) | 2006-04-03 | 2011-10-31 | Сантарис Фарма А/С | Фармацевтическая композиция |
US20070238183A1 (en) * | 2006-04-04 | 2007-10-11 | Stout Robert L | Methods for assessment of cardiovascular disease risk |
CN103554205A (zh) * | 2006-05-05 | 2014-02-05 | Isis制药公司 | 调节gccr的表达的化合物和方法 |
EP2076597A2 (en) * | 2006-10-09 | 2009-07-08 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of pcsk9 |
US8093222B2 (en) * | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
WO2008113832A2 (en) | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA |
JP2010521193A (ja) | 2007-03-22 | 2010-06-24 | サンタリス ファーマ アー/エス | Apo−b100発現の阻害のためのrnaアンタゴニスト化合物 |
RU2015127794A (ru) * | 2007-03-24 | 2018-12-21 | Касл Терапьютикс, ЭлЭлСи | Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в |
JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
JP2010537958A (ja) * | 2007-08-30 | 2010-12-09 | サンタリス ファーマ アー/エス | Fabp4/ap2を調節するためのrnaアンタゴニスト化合物 |
EP2623599B1 (en) | 2007-10-04 | 2019-01-02 | Roche Innovation Center Copenhagen A/S | Micromirs |
EP2268811A1 (en) | 2008-03-07 | 2011-01-05 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
US8492357B2 (en) | 2008-08-01 | 2013-07-23 | Santaris Pharma A/S | Micro-RNA mediated modulation of colony stimulating factors |
ES2616051T3 (es) | 2008-12-02 | 2017-06-09 | Wave Life Sciences Japan, Inc. | Método para la síntesis de ácidos nucleicos modificados en el átomo de fósforo |
WO2010107838A1 (en) | 2009-03-16 | 2010-09-23 | Isis Pharmaceuticals, Inc. | Targeting apolipoprotein b for the reduction of apolipoprotein c-iii |
JP5773535B2 (ja) | 2009-04-24 | 2015-09-02 | ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブRoche Innovation Center Copenhagen A/S | インターフェロンに非応答性のhcv患者の治療のための医薬組成物 |
JP5998326B2 (ja) | 2009-07-06 | 2016-09-28 | ウェイブ ライフ サイエンス リミテッドWave Life Sciences Ltd. | 新規核酸プロドラッグおよびその使用方法 |
US8563528B2 (en) | 2009-07-21 | 2013-10-22 | Santaris Pharma A/S | Antisense oligomers targeting PCSK9 |
EP2488210A4 (en) | 2009-10-12 | 2014-04-30 | Smith Holdings Llc | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING IN VITO OR IN VITRO-ADMINISTERED OLIGONUCLEOTIDE MEDICAMENTS |
US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
US20150038549A1 (en) | 2011-04-20 | 2015-02-05 | Larry J. Smith | Methods and Compositions for Modulating Gene Expression Using Components That Self Assemble in Cells and Produce RNAi Activity |
EP3248982A1 (en) | 2011-07-19 | 2017-11-29 | Wave Life Sciences Ltd. | Thiosulfonate reagents for the synthesis of functionalized nucleic acids |
SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
KR101835401B1 (ko) | 2012-07-13 | 2018-03-08 | 신 니뽄 바이오메디칼 라보라토리즈, 엘티디. | 키랄 핵산 어쥬번트 |
PL2872147T3 (pl) * | 2012-07-13 | 2023-09-25 | Wave Life Sciences Ltd. | Sposób wytwarzania chiralnych oligonukleotydów |
DK2920308T3 (da) * | 2012-10-31 | 2019-04-01 | Ionis Pharmaceuticals Inc | Cancerbehandling |
WO2014076196A1 (en) | 2012-11-15 | 2014-05-22 | Santaris Pharma A/S | Anti apob antisense conjugate compounds |
AU2014211406B2 (en) | 2013-01-30 | 2019-07-18 | Roche Innovation Center Copenhagen A/S | LNA oligonucleotide carbohydrate conjugates |
AU2014254019B2 (en) | 2013-04-18 | 2018-09-27 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
EP3828275A1 (en) | 2013-05-01 | 2021-06-02 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating ttr expression |
ES2688206T3 (es) | 2013-06-17 | 2018-10-31 | Armo Biosciences, Inc. | Procedimiento de evaluación de la identidad y la estabilidad de proteínas |
UA119643C2 (uk) | 2013-06-27 | 2019-07-25 | Рош Інновейшен Сентер Копенгаген А/С | Антисмисловий олігомер та кон'югат, направлений на пропротеїн конвертазу субтилізин/кексин типу 9 (pcsk9) |
CN105658232A (zh) | 2013-08-30 | 2016-06-08 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素-10治疗疾病和病症的方法 |
ES2862139T3 (es) | 2013-11-11 | 2021-10-07 | Armo Biosciences Inc | Procedimientos de uso de Interleucina 10 para el tratamiento de enfermedades y trastornos |
WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
SG10201912897UA (en) | 2014-01-16 | 2020-02-27 | Wave Life Sciences Ltd | Chiral design |
PL3137605T3 (pl) | 2014-05-01 | 2021-04-19 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji białka angiopoetynopodobnego 3 |
CN106573970B (zh) * | 2014-05-15 | 2021-07-30 | 克利夫兰心脏实验室公司 | 用于hdl和apoa1的纯化和检测的组合物和方法 |
CN107847583A (zh) | 2015-05-28 | 2018-03-27 | 阿尔莫生物科技股份有限公司 | 用于治疗癌症的聚乙二醇化白细胞介素‑10 |
US10398761B2 (en) | 2015-08-25 | 2019-09-03 | Armo Biosciences, Inc. | Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers |
KR20180073606A (ko) | 2015-11-06 | 2018-07-02 | 아이오니스 파마수티컬즈, 인코포레이티드 | 아포리포프로테인 (a) 발현 조정 |
CN109661233A (zh) | 2016-10-06 | 2019-04-19 | Ionis 制药公司 | 缀合低聚化合物的方法 |
EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3788914T2 (de) | 1986-09-08 | 1994-08-25 | Ajinomoto Kk | Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere. |
US5712257A (en) * | 1987-08-12 | 1998-01-27 | Hem Research, Inc. | Topically active compositions of mismatched dsRNAs |
WO1989005358A1 (en) | 1987-11-30 | 1989-06-15 | University Of Iowa Research Foundation | Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes |
US5403711A (en) | 1987-11-30 | 1995-04-04 | University Of Iowa Research Foundation | Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved |
US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
US5623065A (en) | 1990-08-13 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
US5220007A (en) | 1990-02-15 | 1993-06-15 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
US5220006A (en) * | 1990-10-23 | 1993-06-15 | The United States Of America As Represented By The Department Of Health And Human Services | Identification of a suppressor of atherogenic apolipoprotein |
US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
US5408038A (en) * | 1991-10-09 | 1995-04-18 | The Scripps Research Institute | Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides |
US5700922A (en) | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
FR2692265B1 (fr) | 1992-05-25 | 1996-11-08 | Centre Nat Rech Scient | Composes biologiquement actifs de type phosphotriesters. |
US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
US5434058A (en) * | 1993-02-09 | 1995-07-18 | Arch Development Corporation | Apolipoprotein B MRNA editing protein compositions and methods |
FR2705099B1 (fr) | 1993-05-12 | 1995-08-04 | Centre Nat Rech Scient | Oligonucléotides phosphorothioates triesters et procédé de préparation. |
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US6235470B1 (en) * | 1993-11-12 | 2001-05-22 | The Johns Hopkins University School Of Medicine | Detection of neoplasia by analysis of saliva |
EP0733059B1 (en) | 1993-12-09 | 2000-09-13 | Thomas Jefferson University | Compounds and methods for site-directed mutations in eukaryotic cells |
US5656612A (en) * | 1994-05-31 | 1997-08-12 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
US5652356A (en) | 1995-08-17 | 1997-07-29 | Hybridon, Inc. | Inverted chimeric and hybrid oligonucleotides |
KR0185334B1 (ko) * | 1995-11-02 | 1999-04-01 | 김은영 | 인간 혈장 아포지단백질 비-100에 결합하는 생쥐 항체를 암호하는 씨디엔에이 |
US6794499B2 (en) * | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
US6156315A (en) * | 1997-10-10 | 2000-12-05 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting the binding of low density lipoprotein to blood vessel matrix |
ZA99133B (en) * | 1998-01-08 | 1999-09-16 | Rhone Poulenc Rorer Pharma | Transgenic rabbit that expresses a functional human lipoprotein (A). |
US6238921B1 (en) * | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
US6949367B1 (en) * | 1998-04-03 | 2005-09-27 | Epoch Pharmaceuticals, Inc. | Modified oligonucleotides for mismatch discrimination |
US5945290A (en) * | 1998-09-18 | 1999-08-31 | Isis Pharmaceuticals, Inc. | Antisense modulation of RhoA expression |
US6172216B1 (en) * | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
AU2001250572A1 (en) * | 2000-04-07 | 2001-10-23 | Epigenomics Ag | Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations |
US6878729B2 (en) * | 2001-05-04 | 2005-04-12 | The Procter & Gamble Company | Medicinal uses of dihydropyrazoles |
US6660737B2 (en) * | 2001-05-04 | 2003-12-09 | The Procter & Gamble Company | Medicinal uses of hydrazones |
US7407943B2 (en) * | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
US7888324B2 (en) * | 2001-08-01 | 2011-02-15 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
WO2003097662A1 (en) * | 2002-05-15 | 2003-11-27 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein b expression |
US7511131B2 (en) * | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
US20060009410A1 (en) * | 2002-11-13 | 2006-01-12 | Crooke Rosanne M | Effects of apolipoprotein B inhibition on gene expression profiles in animals |
AU2003294281B2 (en) * | 2002-11-13 | 2010-05-20 | Kastle Therapeutics, Llc | Antisense modulation of apolipoprotein B expression |
US20050287558A1 (en) * | 2004-05-05 | 2005-12-29 | Crooke Rosanne M | SNPs of apolipoprotein B and modulation of their expression |
EP1786472B1 (en) * | 2004-08-10 | 2013-01-16 | Genzyme Corporation | Antisense modulation of apolipoprotein b expression |
-
2005
- 2005-08-10 EP EP05784428A patent/EP1786472B1/en not_active Not-in-force
- 2005-08-10 ES ES05784428T patent/ES2401114T3/es active Active
- 2005-08-10 AU AU2005272912A patent/AU2005272912A1/en not_active Abandoned
- 2005-08-10 US US11/200,710 patent/US20060035858A1/en not_active Abandoned
- 2005-08-10 ES ES11171206.3T patent/ES2550824T3/es active Active
- 2005-08-10 DK DK15177512.9T patent/DK2997980T3/da active
- 2005-08-10 ES ES15177512.9T patent/ES2663810T3/es active Active
- 2005-08-10 PL PL05784428T patent/PL1786472T3/pl unknown
- 2005-08-10 US US11/573,537 patent/US20090326040A1/en not_active Abandoned
- 2005-08-10 PT PT57844284T patent/PT1786472E/pt unknown
- 2005-08-10 CA CA002576860A patent/CA2576860A1/en active Pending
- 2005-08-10 SI SI200531994T patent/SI2409713T1/sl unknown
- 2005-08-10 HU HUE11171206A patent/HUE026284T2/en unknown
- 2005-08-10 PL PL11171206T patent/PL2409713T3/pl unknown
- 2005-08-10 DK DK05784428.4T patent/DK1786472T3/da active
- 2005-08-10 EP EP11171206.3A patent/EP2409713B1/en not_active Not-in-force
- 2005-08-10 PT PT111712063T patent/PT2409713E/pt unknown
- 2005-08-10 EP EP15177512.9A patent/EP2997980B1/en not_active Not-in-force
- 2005-08-10 WO PCT/US2005/028342 patent/WO2006020676A2/en active Application Filing
-
2011
- 2011-08-19 US US13/214,135 patent/US20120115926A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2409713A1 (en) | 2012-01-25 |
PL1786472T3 (pl) | 2013-06-28 |
US20090326040A1 (en) | 2009-12-31 |
US20060035858A1 (en) | 2006-02-16 |
PL2409713T3 (pl) | 2016-02-29 |
DK2997980T3 (da) | 2018-03-26 |
EP2409713B1 (en) | 2015-07-22 |
HUE026284T2 (en) | 2016-06-28 |
ES2401114T3 (es) | 2013-04-17 |
PT1786472E (pt) | 2013-03-06 |
ES2663810T3 (es) | 2018-04-17 |
EP2997980B1 (en) | 2017-12-20 |
EP1786472A2 (en) | 2007-05-23 |
EP1786472B1 (en) | 2013-01-16 |
SI2409713T1 (sl) | 2015-10-30 |
CA2576860A1 (en) | 2006-02-23 |
WO2006020676A2 (en) | 2006-02-23 |
WO2006020676A3 (en) | 2006-06-08 |
US20120115926A1 (en) | 2012-05-10 |
PT2409713E (pt) | 2015-10-09 |
ES2550824T3 (es) | 2015-11-12 |
AU2005272912A1 (en) | 2006-02-23 |
EP2997980A1 (en) | 2016-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1786472T3 (da) | Antisense-modulering af apolipoprotein B-ekspression | |
DK1745062T3 (da) | Forbedrede modulatorer af koagulationsfaktorer | |
DK1802579T3 (da) | Derivater af 3-arylaminopyridin | |
DK1992697T3 (da) | Fremstilling af TNFR-Fc | |
DK1797183T3 (da) | Regulering af onkogener med mikrornas | |
DK2031063T3 (da) | Modulatorer af duftreceptorer | |
DK3225251T3 (da) | Modulering af pro-neurotrofinaktivitet | |
DE602005011285D1 (de) | Formmasse von polymer | |
DE602005012267D1 (de) | N von geräten | |
DK1778618T3 (da) | Syntese af triethylentetraminer | |
DK1720866T3 (da) | Fremgangsmåde | |
ATE504588T1 (de) | Stabile salze von olanzapin | |
DK2363414T3 (da) | Stedstyret modifikation af FVIII | |
DK2479680T3 (da) | Fremgangsmåde til visning af rate-responsive strømme | |
DK1931350T3 (da) | Administration af inhibitorer af dipeptidylpeptidase | |
DK1718608T3 (da) | Virale polymeraseinhibitorer | |
DK1809302T3 (da) | Antisense-modulation af integrin-alfa-4-ekspression | |
DK1976516T3 (da) | Behandling af viral hepatitis | |
DK1653807T3 (da) | Anvendelse af dermale mikroorganer | |
DK1940465T3 (da) | Ny anvendelse af anti-IL-1beta-antistoffer | |
DK1931315T3 (da) | Depotformuleringer af nalbufin | |
DE602006004463D1 (de) | Kristallform von asenapinmaleat | |
DK1763520T3 (da) | Anvendelse af trisubstituerede benzopyranoner | |
DK1587542T3 (da) | Anvendelse af anti-CD100-antistoffer | |
DK1628504T3 (da) | Strømbesparende drift af høreapparater |